Application value and safety of trilaciclib in first-line chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer: A real-world study.

Oncol Lett · 2025 · PMC12517122 · PMID 41089370

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP=0.057so close (0.05 < p ≤ 0.1)

75.6%), although the difference did not reach statistical significance (P=0.057).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.